Navigation Links
Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
Date:10/14/2008

REINACH, Switzerland, October 14 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that the agency's Anti-Infective Drugs Advisory Committee will discuss the New Drug Application (NDA) for intravenous iclaprim in complicated Skin and Skin Structure Infections (cSSSI) during its meeting on 18-20 November 2008. An Advisory Committee can be requested by FDA as part of the review process of an NDA or supplemental NDA.

Iclaprim is a hospital antibiotic drug candidate with potent bactericidal (killing) activity against MRSA and an extended range of important pathogens. To date, Arpida has filed marketing applications for intravenous iclaprim in the treatment of complicated Skin and Skin Structure Infections in the U.S.A., Canada and the European Union.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "We are delighted to have an opportunity to present iclaprim to leading experts in the anti-infective field and to discuss important features of our NDA with the Advisory Committee."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008. The FDA has defined that the Prescription
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
2. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
3. Arpida Provides Further Comments on the Pivotal Phase III Trials
4. Arpida Invited to Present Data on Iclaprim at Scientific Conference
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
9. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
10. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
11. Burcon announces GRAS status for Puratein(R) & Supertein(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to ... & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), ... QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global ... Oligonucleotide Synthesis Market is expected to reach $1,712.1 ... growing at a CAGR of 9.8% from 2014 ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... VANCOUVER, British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" ... 2014 fiscal year-end financial statements.  The Company recently changed ... to facilitate an application to list its common stock ... possible. DelMar,s financial statements as filed with ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
(Date:9/1/2014)... 2014 The National Association of Hispanic ... Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, PhD, ... Academy of Nursing. They will be inducted with Immediate ... whose induction we reported last May. , Our three ... the 2014 American Academy of Nursing Policy Conference in ...
(Date:9/1/2014)... 01, 2014 Bioinformatics refers to ... analyze biological and genetic data. A major part ... developing software tools to generate and process useful ... with biological computation. While bioinformatics simply makes use ... can its related concepts, biological computation refers to ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ... in September, where issues related to claims involving the ... of Pennsylvania, Bernstein Liebhard LLP reports. , According ... Court’s website, the meeting is scheduled to take place ... the latest of several Tylenol conferences that have taken ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many web ... carefully, Top10BestSEOHosting.com is here to announce that JustHost, ... suppliers in 2014. , JustHost ( http://www.justhost.com/track/seohosts ) ... shared hosting plan. The company’s approach to hosting ... affordable, accessible and powerful enough for anyone to ...
(Date:9/1/2014)... Colorado (PRWEB) August 31, 2014 Daily ... an online resource and community that gives members access ... editing resources. , This online resource aims to help ... as well as artists who are looking for inspiration ... Learn more about Tattoo Me Now by visiting the ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... Atopy (Allergy) Research Center at the Juntendo University School ... their fecal droppings// disrupt immune system in human skin ... ,Episodes of asthma and eczemas have been ... by other researchers. However the present study conducted in ...
... one of the greatest challenges facing researchers today, and recent ... a growing epidemic.// The World Health Organization has estimated that ... problems, of them nearly 300 million are obese. ... works on the source of the problem – appetite, the ...
... with breast cancer positive to hormone receptors and HER2 ... (anastrozole) from AstraZeneca to their treatment improves the length ... Phase III clinical trial sponsored by Roche showed that ... after which the cancer continued to progress. ...
... more people in the Indian capital Tuesday, taking the total ... situation did not warrant declaring it an epidemic. ,"We ... are well equipped to deal with the situation, hence there ... Minister Yoganand Shastri. ,At an emergency cabinet meeting ...
... specific class of antioxidants found in fruit and vegetable ... ,Non-vitamin antioxidants - polyphenols - are abundant in the ... also present in teas and wines. ,Lab ... potent effect on health, with the potential to significantly ...
... risk of coronary heart diseases, say experts."Coronary heart diseases (CHD) ... oil can reduce the risk of CHD," said S.C. Manchanda//, ... India Institute of Medical Sciences (AIIMS). ,Mustard oil ... the lowest amount of saturated fatty acids and a high ...
Cached Medicine News:Health News:Brain behind the Brawn: Vital Molecule in the Brain Controls Appetite 2Health News:Dengue Outbreak in the Capital is not an Epidemic: Government 2Health News:Mustard Oil can Reduce the Risk of Heart Diseases 2
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only...
... Suggested Clinical Applications:, ,Cool Aerosol Therapy. ... open system devices such as aerosol masks, ... that provide only limited FIO2 and limited ... Nebulizer guards against accidental dilution with room ...
... new PARI TREK™ Compact Compressor is for ... aerosol treatments anywhere and everywhere. The compressor ... versatile power source optionsworldwide AC compatibility (100 ... battery, permit patients the freedom to take ...
... ,Allied Healthcares Timeter® PCS 414 portable air ... compressors that you may wonder if its running. ... features a durable, mar-resistant steel case thats easy ... only 26.5 pounds. The PCS 414 has been ...
Medicine Products: